/

RARE

Ultragenyx Pharmaceutical Inc.Open

14.79−0.51 −3.33%USD

NasdaqGS · as of Oct 13, 11:22 ET · 15m delay

Open

15.27

Prev close

15.30

Day range

14.7915.39

52-week range

12.7339.89

Volume

671.34K0.17×

Mkt cap

1.46B

P/E ttm

—

Fwd P/E

24.95

EPS ttm

-5.82

Div yield

0.00%

Earnings

Aug 4, 2026

From 52w high

−62.92%

Price Chart

Yahoo Finance · delayed

RAREOct 13, 2026O 15.27H 15.39L 14.79C 14.79−0.51 (−3.33%)Vol 671.34K

SMA 5019.67
SMA 20023.42

1Y change −52.97% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

RARE Ultragenyx Pharmaceutical Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +2.28%
1 month: +3.43%
3 months: −53.82%
6 months: −39.80%
Year to date: −35.70%
1 year: −53.81%

Valuation & ownership

Market cap: 1.46B
Enterprise value: 2.42B
P/E (ttm): —
Forward P/E: 24.95
PEG ratio: —
Price / book: —
Price / sales (ttm): 2.03
EV / EBITDA: -5.21
EPS (ttm): -5.82
EPS (forward): 0.5927
Beta (5y monthly): 0.35
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 98.59M
Float: 80.42M
Short % of float: 21.35%
Short ratio (days): 2.95
Held by insiders: 3.44%
Held by institutions: 112.48%
Avg volume (3m): 3.91M
50-day average: 19.87
200-day average: 23.52
52-week change: −53.81%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 39.1
vs 50-day SMA: −24.81%
vs 200-day SMA: −36.85%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 6.47%
Realised vol (20d, ann.): 64.3%
From 52-week high: −62.92%
From 52-week low: +16.18%

ANR

Analyst Consensus

19 analysts

Consensus

Buy

2.10 on a 1 (strong buy) – 5 (sell) scale

Mean target

26.79

+81.13% implied

Low 16.00Median 25.00High 39.00

Recommendation trend

Now10 / 10 / 0
1m ago10 / 10 / 0

DES

About Ultragenyx Pharmaceutical Inc.

Yahoo Finance profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 1,371
Headquarters: Novato, CA, United States

SEAS

Seasonality · RARE

2014–2026 · monthly returns

Strongest month Feb +7.28%Weakest month Oct −5.64%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	4.7	-2.8	-10.4	17.9	-3.0	39.5	-25.4	1.2	-40.4	-1.6			−35.7%
2025	2.3	-0.3	-15.6	7.6	-12.7	6.8	-24.9	9.7	0.4	15.0	0.4	-33.8	−45.3%
2024	-7.8	17.3	-9.7	-8.9	-5.6	2.4	9.5	26.1	-2.2	-8.2	-6.6	-11.7	−12.0%
2023	-2.2	-1.9	-9.9	8.9	13.0	-6.5	-6.5	-14.7	-3.1	-0.7	9.7	23.1	+3.2%
2022	-16.8	-3.7	7.9	-2.7	-33.7	27.2	-10.7	-10.5	-13.2	-2.3	-10.3	27.6	−44.9%
2021	0.1	2.1	-19.6	-1.9	-8.9	-6.3	-16.3	20.6	-6.3	-7.0	-10.4	11.8	−39.3%
2020	23.0	6.7	-20.8	36.0	13.3	14.3	-0.1	8.8	-3.4	22.3	18.0	16.8	+224.1%
2019	13.4	30.0	8.1	-4.8	-16.8	15.6	-5.1	-9.6	-21.5	-6.2	-1.2	7.7	−1.8%
2018	15.0	-10.4	6.7	-0.3	44.0	5.0	2.9	7.1	-9.9	-36.5	10.8	-19.0	−6.3%
2017	6.7	13.4	-20.3	-5.0	-16.4	15.3	6.8	-14.0	-6.7	-13.5	9.5	-8.1	−34.0%
2016	-49.9	8.6	3.8	6.8	8.1	-33.1	29.4	4.2	7.6	-16.8	32.7	-10.2	−37.3%
2015	32.4	-6.6	14.4	-9.1	54.2	17.7	18.1	-7.7	-13.7	3.2	-1.0	14.1	+155.7%
2014		32.0	-12.3	-20.7	-3.1	19.5	-2.7	22.1	6.1	-16.9	-7.3	0.7	+3.9%

INSD

Insider Activity · RARE

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

324.6K shares

Sells, 6 months

32.1K shares

Net shares

+292.6K

Net change in insider shares

+9.50%

Date	Insider	Transaction	Shares	Value
Sep 14, 2026	Huizenga Theodore AlanOfficer	Sale at price 13.57 per share.	1.3K	$17.41K
Sep 2, 2026	Huizenga Theodore AlanOfficer

CONG

Congress Trades · RARE

House and Senate reports since 2025

Members

1 last bought

Buys

~$32.0K

Sells

~$0

Net

+$32.0K

est. bought − sold

Latest

Mar 3, 26

Gilbert Cisneros

Members who traded it

Member	Buys	Sells	Est. net	Last move
Gilbert Cisneros CA31	4		+$32.0K	Bought Mar 3, 26

Bought and sold by quarter (est.)

Members of Congress's RARE trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Mar 3, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Apr 7, 26 (35d)	PDF
Feb 18, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Mar 9, 26 (19d)	PDF
Aug 8, 25	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Sep 12, 25 (35d)	PDF
Jul 15, 25	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Aug 14, 25 (30d)	PDF

From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

13F

Investors Holding RARE

latest 13F filings of 29 followed managers

Investors holding RARE
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$13.8M	0.02%	413.70K	−26%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

RARE

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

RARE

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ultragenyx Pharmaceutical Inc.

Seasonality · RARE

Insider Activity · RARE

Congress Trades · RARE

Members who traded it

Bought and sold by quarter (est.)

Investors Holding RARE

Investors Holding RARE

Congress Trades · RARE

Members who traded it

Bought and sold by quarter (est.)

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ultragenyx Pharmaceutical Inc.

Insider Activity · RARE

Financial Snapshot

Earnings & Dividends

News

Seasonality · RARE